ESTRO 2024 - Abstract Book

S1033

Clinical - Gynaecology

ESTRO 2024

The negative impact of SO on OS suggests that this factor may be a relevant and emerging prognostic element in the LACC setting. Therefore, nutritional status and body composition, particularly the presence of SO, should be further explored and considered in the development of future predictive-prognostic models for patients with LACC. Additionally, correcting anemia remains a critical element for improving the prognosis of LACC patients undergoing concurrent chemoradiation.

Keywords: sarcopenic obesity, cervical cancer, prognosis

1169

Digital Poster

Is Haemoglobin of 120g/l during definitive CRT in patients with cervical cancer of prognostic value?

Nida Hassan, Mau-Don Phan

South Wales Cancer Centre, Clinical Oncology, Swansea, United Kingdom

Purpose/Objective:

Cervical cancer remains a leading cause of mortality and morbidity amongst women worldwide. A low haemoglobin level due to vaginal blood loss, chronic disease and other factors has been associated with inferior local tumour control (theoretically due to increased radio resistance in hypoxic tumour). This hypothesis has informed local practice (RCR 2019) 1 across the globe despite lack of contemporary randomised evidence (Winter 2004) 2 . At our centre, patients with locally advanced cervix cancer (LACC) are transfused before and during definitive chemoradiation with concurrent cisplatin in order to maintain a haemoglobin level of 120 g/l despite significant resource constraints. A recent international expert consensus guideline proposed a transfusion target between 90 and 120 g/l (Zayed 2021) 3 . The purpose of this retrospective study is to investigate relationship between a range of haemoglobin levels maintained during definitive chemoradiation, local control and progression-free-survival (PFS) at 1 year and overall survival (OS) at 1 year amongst women with locally advanced cervical cancer (LACC) treated with definitive chemoradiation with weekly concurrent cisplatin, simultaneous integrated nodal boosting and intracavitory brachytherapy.

Material/Methods:

We retrospectively analysed 87 LACC patients {FIGO stage II B-IVA (FIGO 2018)} who underwent Volumetric Modulated Arc Therapy (VMAT) with concurrent cisplatin, intra-cavitary brachytherapy (ICBT) +/- Simultaneous Integrated Boost to any involved lymph nodes between 2017 and 2023. All patients were analysed in terms of patient demographics, tumour, treatment and other prognostic factors such as nodal status, haemoglobin (Hb) at baseline and measured weekly during RT. Patients were grouped according to maintained haemoglobin level during treatment. Endpoints were local control, progression-free survival (assessed by the Kaplan-Meier method with the log-rank test) and overall survival at 1 year.